To the Editor Siu and colleagues¹ conducted the largest clinical trial to date to assess accelerated-fractionation radiotherapy (AFX) plus panitumumab compared with standard-fractionation radiotherapy (SFX) plus cisplatin. The study was designed for a superiority analysis to detect a difference in the progression-free survival (PFS) that corresponds to a hazard ratio (HR) of 0.70, requiring a total of 246 events and 320 patients to achieve appropriate statistical power. If superiority was not demonstrated, the study tested noninferiority of AFX plus panitumumab to SFX plus cisplatin with a noninferiority margin of 1.15. The study was unable to demonstrate either the superiority or noninferiority of AFX plus panitumumab to SFX plus cisplatin.